Summary
Global Markets Direct’s, ‘Osteoarthritis Pain - Pipeline Review, H1 2016’, provides an overview of the Osteoarthritis Pain pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Osteoarthritis Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis Pain and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain
- The report reviews pipeline therapeutics for Osteoarthritis Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Osteoarthritis Pain therapeutics and enlists all their major and minor projects
- The report assesses Osteoarthritis Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Osteoarthritis Pain
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
Addex Therapeutics Ltd
Afferent Pharmaceuticals, Inc.
Akron Molecules AG
Allergan Plc
Ampio Pharmaceuticals, Inc.
AnaMar AB
Antibe Therapeutics, Inc.
Aralez Pharmaceuticals Inc.
Arena Pharmaceuticals, Inc.
Array BioPharma Inc.
AskAt Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Axsome Therapeutics, Inc.
Biogen, Inc.
Boehringer Ingelheim GmbH
Bone Medical Limited
Carbylan Therapeutics, Inc.
Centrexion Corporation
Eli Lilly and Company
Elite Pharmaceuticals, Inc.
Flexion Therapeutics, Inc.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
Grunenthal GmbH
Iroko Pharmaceuticals, LLC
Novartis AG
Nuvo Pharmaceuticals Inc.
Pfizer Inc.
Phosphagenics Limited
pSivida Corp.
Purdue Pharma L.P.
Regeneron Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Osteoarthritis Pain Overview 9
Therapeutics Development 10
Pipeline Products for Osteoarthritis Pain - Overview 10
Pipeline Products for Osteoarthritis Pain - Comparative Analysis 11
Osteoarthritis Pain - Therapeutics under Development by Companies 12
Osteoarthritis Pain - Therapeutics under Investigation by Universities/Institutes 15
Osteoarthritis Pain - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Osteoarthritis Pain - Products under Development by Companies 20
Osteoarthritis Pain - Products under Investigation by Universities/Institutes 23
Osteoarthritis Pain - Companies Involved in Therapeutics Development 24
AbbVie Inc. 24
Addex Therapeutics Ltd 25
Afferent Pharmaceuticals, Inc. 26
Akron Molecules AG 27
Allergan Plc 28
Ampio Pharmaceuticals, Inc. 29
AnaMar AB 30
Antibe Therapeutics, Inc. 31
Aralez Pharmaceuticals Inc. 32
Arena Pharmaceuticals, Inc. 33
Array BioPharma Inc. 34
AskAt Inc. 35
Astellas Pharma Inc. 36
AstraZeneca Plc 37
Axsome Therapeutics, Inc. 38
Biogen, Inc. 39
Boehringer Ingelheim GmbH 40
Bone Medical Limited 41
Carbylan Therapeutics, Inc. 42
Centrexion Corporation 43
Eli Lilly and Company 44
Elite Pharmaceuticals, Inc. 45
Flexion Therapeutics, Inc. 46
GlaxoSmithKline Plc 47
Glenmark Pharmaceuticals Ltd. 48
Grunenthal GmbH 49
Iroko Pharmaceuticals, LLC 50
Novartis AG 51
Nuvo Pharmaceuticals Inc. 52
Pfizer Inc. 53
Phosphagenics Limited 54
pSivida Corp. 55
Purdue Pharma L.P. 56
Regeneron Pharmaceuticals, Inc. 57
Vertex Pharmaceuticals Incorporated 58
Osteoarthritis Pain - Therapeutics Assessment 59
Assessment by Monotherapy Products 59
Assessment by Combination Products 60
Assessment by Target 61
Assessment by Mechanism of Action 64
Assessment by Route of Administration 67
Assessment by Molecule Type 69
Drug Profiles 71
(amlodipine besylate + celecoxib) - Drug Profile 71
(hyaluronate sodium + triamcinolone acetonide) - Drug Profile 73
(lidocaine + tetracaine) - Drug Profile 74
(naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile 76
AAT-008 - Drug Profile 78
adefovir dipivoxil - Drug Profile 79
ADX-71441 - Drug Profile 80
AF-219 - Drug Profile 82
AMAP-102 - Drug Profile 85
Ampion - Drug Profile 87
APD-371 - Drug Profile 89
AQU-010 - Drug Profile 90
ARRY-954 - Drug Profile 91
AS-288640100 - Drug Profile 92
ATB-346 - Drug Profile 93
AXIBU-01 - Drug Profile 95
BI-1026706 - Drug Profile 96
calcitonin - Drug Profile 97
capsaicin - Drug Profile 99
cebranopadol - Drug Profile 101
celecoxib - Drug Profile 103
CGS-125 - Drug Profile 104
CR-4056 - Drug Profile 105
CRB-0089 - Drug Profile 106
duloxetine hydrochloride DR - Drug Profile 107
ELS-130 - Drug Profile 109
EMA-401 - Drug Profile 110
fasinumab - Drug Profile 112
fluticasone propionate - Drug Profile 114
grapiprant - Drug Profile 115
GRC-27864 - Drug Profile 117
GSK-3196165 - Drug Profile 118
ibuprofen - Drug Profile 120
MEDI-7352 - Drug Profile 121
naproxen sodium - Drug Profile 122
NEO-5024 - Drug Profile 124
NEO-5937 - Drug Profile 125
NEO-6860 - Drug Profile 126
OLT-1177 - Drug Profile 127
onabotulinumtoxin A - Drug Profile 128
oxycodone ER - Drug Profile 131
PA-300 DR - Drug Profile 133
PA-65020 - Drug Profile 134
Small Molecule for Osteoarthritis Pain - Drug Profile 135
Small Molecule to Antagonize P2Y14 for Osteoarthritic Pain - Drug Profile 136
Small Molecules for Osteoarthritis Pain - Drug Profile 137
Small Molecules to Block Calcium Ion Channel for Osteoarthritis Pain - Drug Profile 138
Small Molecules to Block Nav1.7 for Osteoarthritis Pain - Drug Profile 139
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile 140
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile 141
Small Molecules to Inhibit PDE2 for Osteoarthritis Pain - Drug Profile 142
tanezumab - Drug Profile 143
triamcinolone acetonide sodium phosphate SR - Drug Profile 146
V-116517 - Drug Profile 148
VG-201 - Drug Profile 149
VX-150 - Drug Profile 150
zoledronic acid - Drug Profile 151
Osteoarthritis Pain - Recent Pipeline Updates 153
Osteoarthritis Pain - Dormant Projects 190
Osteoarthritis Pain - Discontinued Products 195
Osteoarthritis Pain - Product Development Milestones 197
Featured News & Press Releases 197
Appendix 205
Methodology 205
Coverage 205
Secondary Research 205
Primary Research 205
Expert Panel Validation 205
Contact Us 205
Disclaimer 206
List of Tables
Number of Products under Development for Osteoarthritis Pain, H1 2016 14
Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Number of Products under Development by Companies, H1 2016 (Contd..1) 17
Number of Products under Development by Companies, H1 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2016 19
Comparative Analysis by Late Stage Development, H1 2016 20
Comparative Analysis by Clinical Stage Development, H1 2016 21
Comparative Analysis by Early Stage Development, H1 2016 22
Comparative Analysis by Unknown Stage Development, H1 2016 23
Products under Development by Companies, H1 2016 24
Products under Development by Companies, H1 2016 (Contd..1) 25
Products under Development by Companies, H1 2016 (Contd..2) 26
Products under Investigation by Universities/Institutes, H1 2016 27
Osteoarthritis Pain - Pipeline by AbbVie Inc., H1 2016 28
Osteoarthritis Pain - Pipeline by Addex Therapeutics Ltd, H1 2016 29
Osteoarthritis Pain - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016 30
Osteoarthritis Pain - Pipeline by Akron Molecules AG, H1 2016 31
Osteoarthritis Pain - Pipeline by Allergan Plc, H1 2016 32
Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 33
Osteoarthritis Pain - Pipeline by AnaMar AB, H1 2016 34
Osteoarthritis Pain - Pipeline by Antibe Therapeutics, Inc., H1 2016 35
Osteoarthritis Pain - Pipeline by Aralez Pharmaceuticals Inc., H1 2016 36
Osteoarthritis Pain - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 37
Osteoarthritis Pain - Pipeline by Array BioPharma Inc., H1 2016 38
Osteoarthritis Pain - Pipeline by AskAt Inc., H1 2016 39
Osteoarthritis Pain - Pipeline by Astellas Pharma Inc., H1 2016 40
Osteoarthritis Pain - Pipeline by AstraZeneca Plc, H1 2016 41
Osteoarthritis Pain - Pipeline by Axsome Therapeutics, Inc., H1 2016 42
Osteoarthritis Pain - Pipeline by Biogen, Inc., H1 2016 43
Osteoarthritis Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2016 44
Osteoarthritis Pain - Pipeline by Bone Medical Limited, H1 2016 45
Osteoarthritis Pain - Pipeline by Carbylan Therapeutics, Inc., H1 2016 46
Osteoarthritis Pain - Pipeline by Centrexion Corporation, H1 2016 47
Osteoarthritis Pain - Pipeline by Eli Lilly and Company, H1 2016 48
Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals, Inc., H1 2016 49
Osteoarthritis Pain - Pipeline by Flexion Therapeutics, Inc., H1 2016 50
Osteoarthritis Pain - Pipeline by GlaxoSmithKline Plc, H1 2016 51
Osteoarthritis Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 52
Osteoarthritis Pain - Pipeline by Grunenthal GmbH, H1 2016 53
Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals, LLC, H1 2016 54
Osteoarthritis Pain - Pipeline by Novartis AG, H1 2016 55
Osteoarthritis Pain - Pipeline by Nuvo Pharmaceuticals Inc., H1 2016 56
Osteoarthritis Pain - Pipeline by Pfizer Inc., H1 2016 57
Osteoarthritis Pain - Pipeline by Phosphagenics Limited, H1 2016 58
Osteoarthritis Pain - Pipeline by pSivida Corp., H1 2016 59
Osteoarthritis Pain - Pipeline by Purdue Pharma L.P., H1 2016 60
Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 61
Osteoarthritis Pain - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 62
Assessment by Monotherapy Products, H1 2016 63
Assessment by Combination Products, H1 2016 64
Number of Products by Stage and Target, H1 2016 66
Number of Products by Stage and Mechanism of Action, H1 2016 69
Number of Products by Stage and Route of Administration, H1 2016 72
Number of Products by Stage and Molecule Type, H1 2016 74
Osteoarthritis Pain Therapeutics - Recent Pipeline Updates, H1 2016 157
Osteoarthritis Pain - Dormant Projects, H1 2016 194
Osteoarthritis Pain - Dormant Projects (Contd..1), H1 2016 195
Osteoarthritis Pain - Dormant Projects (Contd..2), H1 2016 196
Osteoarthritis Pain - Dormant Projects (Contd..3), H1 2016 197
Osteoarthritis Pain - Dormant Projects (Contd..4), H1 2016 198
Osteoarthritis Pain - Discontinued Products, H1 2016 199
Osteoarthritis Pain - Discontinued Products (Contd..1), H1 2016 200
List of Figures
Number of Products under Development for Osteoarthritis Pain, H1 2016 14
Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Number of Products under Investigation by Universities/Institutes, H1 2016 19
Comparative Analysis by Clinical Stage Development, H1 2016 21
Comparative Analysis by Early Stage Products, H1 2016 22
Assessment by Monotherapy Products, H1 2016 63
Assessment by Combination Products, H1 2016 64
Number of Products by Top 10 Targets, H1 2016 65
Number of Products by Stage and Top 10 Targets, H1 2016 65
Number of Products by Top 10 Mechanism of Actions, H1 2016 68
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 68
Number of Products by Top 10 Routes of Administration, H1 2016 71
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 71
Number of Products by Molecule Types, H1 2016 73
Number of Products by Stage and Molecule Types, H1 2016 73
